Or click here to register offline.

Exhibits By:

Media Partners:



Join ISBioTech on:
Manuel J.T. Carrondo, PhD
Instituto de Biologia Experimental e Tecnológica (iBET)
Clifton E. McPherson, PhD
Protein Sciences Corporation
Otto-Wilhelm Merten, PhD
Amine A. Kamen, PhD
McGill University
Martin A. Giedlin, PhD
Novartis Pharmaceuticals Corporation

Dominic Esposito, PhD
Director, Protein Expression Laboratory
Frederick National Laboratory for Cancer Research
The Complete Genome Sequence of a Trichoplusia ni Cell Line, Tni-FNL


We have determined the complete genome sequence of a Trichoplusia ni cell line, Tni-FNL, to the highest quality and completeness of any lepidopteran organism sequenced to date. We will present data on the methodology used to map the genomic sequence along with bioinformatic analysis discussing similarities and differences among the sequenced lepidopteran hosts. In addition, we will discuss some of the unique characteristics of this cell line which may be responsible for its ability to produce higher levels of recombinant proteins than other cell lines, including commercially available lines such as High Five.


Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) at the Frederick National Laboratory for Cancer Research (FNL) in Maryland. The PEL primarily generates DNA and protein reagents for the NCI national mission to target KRAS-driven cancers, as well as supporting NCI and NIH intramural investigators in production of difficult proteins. Prior to his role as director, Dr. Esposito led the Clone Optimization Group in the PEL for nine years and was responsible for the generation of over 15,000 expression clones, 400 new expression vectors, and several technological innovations in protein expression. Dr. Esposito received his BA in Chemistry at La Salle University in Philadelphia, and his PhD in Biochemistry at the Johns Hopkins University Bloomberg School. Dr. Esposito previously worked for Life Technologies, where he helped to develop the Gateway recombinational cloning system.

Nicole Faust, PhD
Chief Scientific Officer, Cevec Pharmaceuticals GmbH
CAP-GT, a Platform Addressing the Production Challenge


Nicole Faust is Chief Scientific Officer and Managing Director at CEVEC Pharmaceuticals, overseeing the company´s activities in gene therapy vector production and recombinant glycoprotein expression. Over the last 18 years she has held scientific management positions with several biotech companies. Before joining CEVEC in 2011, she worked with Lonza as Director R&D combining her expertise in cell biology and gene transfer technology to develop cell-based assays. Prior to Lonza she was heading the Molecular Technology Department at Artemis/Taconic Biosciences, using site-specific recombination and gene editing technologies for the development of pharmaceutically relevant animal models. Nicole holds an MBA degree from Educatis University, Switzerland and she received her PhD in Molecular and Cell Biology from University of Freiburg and spent her postdoctoral period at EMBL, Heidelberg, where she worked on embryonic stem cells and cell differentiation within the hematopoietic system.

Ana Sofia Coroadinha, PhD
Head of Cell Line Development and Molecular Biotechnology Laboratory
Instituto de Biologia Experimental e Tecnológica (iBET)
Novel Stable Lentiviral Vector Producer Cells: Overcoming Viral Vector Cytotoxicity
Etienne Boutry
Director Bioprocess R&D Europe, Sanofi Pasteur SA
Challenges in Process Development and Industrialization of Live Virus Vaccine:
Dengue and Flavivirus Experience on a Vero Cell Line
Lesley Chan, PhD
Scientist II, Vector Process Development & Manufacturing, bluebird bio Inc.
The Development and Intensification of a
Lentiviral Vector Manufacturing Process Using Stable Cell Lines
Charlotte Dyring, PhD
COO & Co-Founder, ExpreS2ion Biotechnologies
Nathalie A. Clément, PhD
Associate Director, PGTC Vector Core Laboratory, University of Florida
Christopher W. Kemp, PhD
President, Kempbio, Inc.
Helen Maunder, PhD
Principal Scientist, Oxford BioMedica plc
James J. Mule, PhD
Executive Vice President Applied Science
H. Lee Moffitt Cancer Center & Research Institute

International Society for BioProcess Technology
110 Willow Grove Ct., Norfolk, Virginia 23505 USA • Phone: 757.467.8903, Fax: 757.257.3800
Web: • Email: